Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Holdings Raised by Hexagon Capital Partners LLC

Hexagon Capital Partners LLC increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 74.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 138 shares of the pharmaceutical company’s stock after purchasing an additional 59 shares during the quarter. Hexagon Capital Partners LLC’s holdings in Vertex Pharmaceuticals were worth $58,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. University of Texas Texas AM Investment Managment Co. purchased a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $25,000. Arlington Trust Co LLC boosted its position in shares of Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 33 shares during the period. Annapolis Financial Services LLC purchased a new position in shares of Vertex Pharmaceuticals during the first quarter valued at $27,000. ICA Group Wealth Management LLC acquired a new position in Vertex Pharmaceuticals during the fourth quarter valued at $28,000. Finally, Fortitude Family Office LLC purchased a new stake in Vertex Pharmaceuticals in the 4th quarter worth about $30,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $471.72, for a total transaction of $1,075,521.60. Following the sale, the chief marketing officer now directly owns 30,099 shares of the company’s stock, valued at $14,198,300.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Ourania Tatsis sold 2,350 shares of the company’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $439.11, for a total value of $1,031,908.50. Following the sale, the executive vice president now owns 53,523 shares of the company’s stock, valued at approximately $23,502,484.53. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CMO Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $471.72, for a total transaction of $1,075,521.60. Following the transaction, the chief marketing officer now directly owns 30,099 shares of the company’s stock, valued at $14,198,300.28. The disclosure for this sale can be found here. Insiders have sold a total of 28,366 shares of company stock valued at $13,058,787 over the last quarter. 0.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms recently commented on VRTX. Piper Sandler raised their price target on shares of Vertex Pharmaceuticals from $450.00 to $456.00 and gave the stock an “overweight” rating in a report on Tuesday, May 7th. Redburn Atlantic started coverage on Vertex Pharmaceuticals in a report on Thursday, June 27th. They set a “buy” rating and a $545.00 price objective for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 7th. Canaccord Genuity Group reissued a “sell” rating and issued a $371.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday, April 12th. Finally, Royal Bank of Canada cut their price objective on shares of Vertex Pharmaceuticals from $424.00 to $421.00 and set a “sector perform” rating on the stock in a research report on Tuesday, June 11th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $448.61.

Vertex Pharmaceuticals Price Performance

Shares of VRTX stock opened at $471.25 on Tuesday. Vertex Pharmaceuticals Incorporated has a 12 month low of $335.82 and a 12 month high of $486.42. The company has a market capitalization of $121.61 billion, a P/E ratio of 30.58, a P/E/G ratio of 2.41 and a beta of 0.39. The stock has a 50 day moving average of $444.89 and a two-hundred day moving average of $426.80. The company has a current ratio of 3.50, a quick ratio of 3.29 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.66 by $1.10. The firm had revenue of $2.69 billion for the quarter, compared to analyst estimates of $2.58 billion. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.67 EPS. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.22 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.